Combination of rapamycin and IL-2 do not affect antigen presentation ability of rat B cell and could promote Tregs proliferation and inhibitory activity

Cellular Immunology
Chuntao ZhangYouping Li

Abstract

Rapamycin (RPM), a powerful agent used clinically in transplant recipients, induces CD4(+)CD25(+) regulatory T cells (Tregs) which play an important role in induction of immune tolerance. However, long-term use of RPM has negative side effects. In this report, we found that combination with the low dose RPM and high dose IL-2 did not affect antigen presentation of rat B cells to Tregs, and could efficiently promote Tregs proliferation and enhance their inhibitory activities in vitro. In addition, the combination of low dose RPM and high dose IL-2 enhanced mRNA expression of Foxp3, TGF-beta1 and Pim-2 in Tregs but not in CD4(+)CD25(-) T effector cells (Teffs). The Tregs inhibitory activity is positively associated with mRNA expressions of TGF-beta1 and Pim-2 while unrelated to the Foxp3 mRNA expression. Our present study offers one approach to expand functional Tregs in vitro, which maybe used for clinical immune tolerance induction.

References

Sep 18, 2002·The Journal of Experimental Medicine·Gláucia C FurtadoJuan J Lafaille
Jan 11, 2003·Science·Shohei HoriShimon Sakaguchi
Mar 4, 2003·Nature Immunology·Roli KhattriFred Ramsdell
Jul 23, 2003·The Journal of Experimental Medicine·Sayuri YamazakiRalph M Steinman
Oct 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Susann StephanDebabrata Mukhopadhyay
Mar 5, 2005·Blood·Manuela BattagliaMaria-Grazia Roncarolo
Dec 11, 2007·Nature Medicine·Olivier JoffreJoost P M van Meerwijk
Jan 14, 2009·Translational Research : the Journal of Laboratory and Clinical Medicine·Guliang XiaXunrong Luo

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.